Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00398372 · ClinicalTrials.gov registry record · NA
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
A NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT00398372: Completed NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin, sponsored by Stanford University.
NCT00398372 is a NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin that has completed, run by Stanford University. The registered enrollment target is 500 participants, above the 381-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (31% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00398372, a NA study of Lymphoma, Non-Hodgkin and Lymphomas: Non-Hodgkin, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG Epratuzumab
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2000-11 |
| Est. Completion | 2009-09 |
| Phase | NA |
What the finished NCT00398372 record still lists
NCT00398372 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 381-participant average among 58 other Lymphoma, Non-Hodgkin trials with a reported enrollment target (31% higher).
The record links to 9 conditions, with Lymphoma, Non-Hodgkin appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT00398372 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00398372 about?
NCT00398372 is a clinical study titled "Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment". To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
What is the current status of trial NCT00398372?
This trial is currently completed. It is a NA study. The enrollment target is 500 participants. The study started on 2000-11. Estimated completion is 2009-09.
What conditions does trial NCT00398372 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin, Lymphomas: Non-Hodgkin, Lymphomas: Non-Hodgkin Cutaneous Lymphoma, Lymphomas: Non-Hodgkin Diffuse Large B-Cell, Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell.
What interventions are being tested in trial NCT00398372?
The interventions under investigation include: Rituximab (DRUG), Epratuzumab (DRUG).
Who is sponsoring clinical trial NCT00398372?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00398372 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Non-Hodgkin
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00398372's enrollment target sits among peer trials
500 7th of 58 higher than 51 of 58 other Lymphoma, Non-Hodgkin trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma, Non-Hodgkin trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
RECRUITING · NA
-
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
ACTIVE NOT RECRUITING · NA
-
Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members
COMPLETED · NA
-
A Study of Azidothymidine (AZT) in the Treatment of HIV Infection in Patients Receiving a Bone Marrow Transplant
COMPLETED · NA
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia